当前位置: 首页 >> 检索结果
563. Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
作者: Anna Meta Dyrvig Kristensen.;Xavier Rossello.;Dan Atar.;Troels Yndigegn.;Takeshi Kimura.;Roberto Latini.;Bertil Lindahl.;Sigrun Halvorsen.;Michael Hecht Olsen.;Valentin Fuster.;Robin Hofmann.;Kjell Vikenes.;Michael Maeng.;David Erlinge.;Stuart Pocock.;Patric Karlström.;Arnhild Bakken.;Theis Lange.;Jose A Barrabés.;Jocelyne Benatar.;Sergio Raposeiras-Roubin.;Claes Held.;Massimo Piepoli.;Morten Wang Fagerland.;Therese Holmager.;Neiko Ozasa.;Eva Irene Bossano Prescott.;John Munkhaugen.;Tomas Jernberg.;Borja Ibanez.; .
来源: N Engl J Med. 2026年394卷6期540-550页
The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear.
565. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.
作者: Luke J Laffin.;Stephen J Nicholls.;Russell S Scott.;Peter M Clifton.;John Baker.;Ashish Sarraju.;Shweta Singh.;Qiuqing Wang.;Kathy Wolski.;Huansheng Xu.;Jen Nielsen.;Naimish Patel.;Jason M Duran.;Steven E Nissen.
来源: N Engl J Med. 2025年393卷21期2119-2130页
Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides and a decreased lifetime risk of atherosclerotic cardiovascular disease.
566. A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.
作者: Tarik Asselah.;Michael A Chattergoon.;Alina Jucov.;Anca Streinu-Cercel.;Pietro Lampertico.;Heiner Wedemeyer.;Patrick T Kennedy.;Edward J Gane.;Brianna L Bullard.;Sophia Chow.;Desiree Santos.;Gregory Camus.;Yimeng Lu.;Cara Pilowa.;Carey Hwang.;Todd Correll.;Kosh Agarwal.; .
来源: N Engl J Med. 2026年394卷4期343-353页
Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D virus (HDV) infection are unknown.
567. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.
作者: Atul Verma.;David H Birnie.;Chenyang Jiang.;Hein Heidbüchel.;Gerhard Hindricks.;Paulus Kirchhof.;Jeff S Healey.;Yunhe Wang.;Nikolaos Dagres.;Marc W Deyell.;Prashanthan Sanders.;Rajeev K Pathak.;Pieter Koopman.;Dieter Nuyens.;Paul Novak.;Guy Amit.;Charles Dussault.;Bhavanesh Makanjee.;F Russell Quinn.;Umjeet Jolly.;Leon Iden.;Malte Kuniss.;Mukul Sharma.;Andrew Ha.;Vidal Essebag.;Jean Champagne.;Michael D Hill.;Eric E Smith.;George A Wells.; .
来源: N Engl J Med. 2026年394卷4期323-332页
Whether successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy is unknown.
569. Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
作者: Vlado Perkovic.;Hernán Trimarchi.;Vladimir Tesar.;Richard Lafayette.;Muh Geot Wong.;Jonathan Barratt.;Yusuke Suzuki.;Adrian Liew.;Hong Zhang.;Kevin Carroll.;Vivekanand Jha.;Alejandra Quevedo.;Seung Hyeok Han.;Manuel Praga.;Bobby Chacko.;Manisha Sahay.;Chee Kay Cheung.;Laura Kooienga.;Michael Walsh.;Jing Xia.;Cecile Fajardo.;Lokesh Shah.;Jeffrey Hafkin.;Dana V Rizk.; .
来源: N Engl J Med. 2026年394卷7期635-646页
The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and inhibits APRIL.
571. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
作者: Erin A Bohula.;Nicholas A Marston.;Ajay K Bhatia.;Gaetano M De Ferrari.;Lawrence A Leiter.;Jose C Nicolau.;Jeong-Gun Park.;Julia F Kuder.;Sabina A Murphy.;Emileigh Walsh.;Huei Wang.;Vladimir Blaha.;Andrzej Budaj.;Jan H Cornel.;Assen Goudev.;Robert Gabor Kiss.;Alberto J Lorenzatti.;Alexander Parkhomenko.;Marcoli Cyrille.;Gabriel Paiva da Silva Lima.;E Magnus Ohman.;Robert P Giugliano.;Marc S Sabatine.; .
来源: N Engl J Med. 2026年394卷2期117-127页
The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, stroke, or symptomatic peripheral artery disease. The effect of evolocumab on the risk of MACE among patients without a previous myocardial infarction or stroke is unknown.
575. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.
作者: Nicholas A Marston.;Brian A Bergmark.;Veronica J Alexander.;Thomas A Prohaska.;Yu Mi Kang.;Filipe A Moura.;Andre Zimerman.;Elaine Waldman.;Julia Weinland.;Sabina A Murphy.;Erica L Goodrich.;Shuanglu Zhang.;Shuting Xia.;Dan Li.;Anne C Goldberg.;Assen Goudev.;Lina Badimon.;Robert Gabor Kiss.;Michal Vrablik.;Daniel Gaudet.;Philippe Moulin.;Erik S G Stroes.;Maciej Banach.;Hofit Cohen.;Dirk Blom.;Min-Ji Charng.;Børge G Nordestgaard.;Stephen J Nicholls.;Sotirios Tsimikas.;Robert P Giugliano.;Marc S Sabatine.; .
来源: N Engl J Med. 2026年394卷5期429-441页
Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III messenger RNA, have not been established in this population.
576. Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
作者: Seung-Jun Lee.;Hee Tae Yu.;Yong-Joon Lee.;Sang-Hyup Lee.;Jung Ho Heo.;Sung Gyun Ahn.;Sanghoon Shin.;Joon-Hyung Doh.;Ae-Young Her.;Byung-Ryul Cho.;Gwang-Sil Kim.;Taek-Geun Kwon.;Sang-Wook Lim.;Jaemin Shim.;Ji-Yong Jang.;Kyounghoon Lee.;Yun-Hyeong Cho.;Cheol Ung Choi.;Sang-Rok Lee.;Hyung-Bok Park.;Han Cheol Lee.;Seunghwan Kim.;Kyeong Ho Yun.;Jong-Hwa Ahn.;Byoung-Kwon Lee.;Deok-Kyu Cho.;Song-Yi Kim.;Ung Kim.;Tae Soo Kang.;Seong Huan Choi.;Won-Ho Kim.;Jin Bae Lee.;Moo-Yong Rhee.;Jin-Bae Kim.;Sang-Ho Jo.;Dae Woo Hyun.;Daehoon Kim.;Tae-Hoon Kim.;Sung-Jin Hong.;Jae-Sun Uhm.;Dong-Ho Shin.;Chul-Min Ahn.;Byeong-Keuk Kim.;Boyoung Joung.;Young-Guk Ko.;Donghoon Choi.;Myeong-Ki Hong.;Yangsoo Jang.;Hui-Nam Pak.;Jung-Sun Kim.; .
来源: N Engl J Med. 2026年394卷7期658-668页
Despite guideline recommendations, evidence for the use of non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with atrial fibrillation after implantation of a drug-eluting stent remains limited.
577. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
作者: Charmaine E Lok.;Michael Farkouh.;Brenda R Hemmelgarn.;Louise M Moist.;Kevan R Polkinghorne.;George Tomlinson.;Paul Tam.;Marcello Tonelli.;Jacob A Udell.; .
来源: N Engl J Med. 2026年394卷2期128-137页
Cardiovascular disease is the leading cause of death in patients receiving hemodialysis, yet effective preventive therapies remain limited. Supplementation with n-3 polyunsaturated fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may have cardiovascular benefits in the general population, but efficacy among patients receiving hemodialysis is uncertain.
579. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.
作者: Richard Lafayette.;Sean J Barbour.;Robert M Brenner.;Kirk N Campbell.;Tom Doan.;Necmi Eren.;Jürgen Floege.;Vivekanand Jha.;Beom Seok Kim.;Adrian Liew.;Bart Maes.;Atanu Pal.;Roberto Pecoits-Filho.;Richard K S Phoon.;Dana V Rizk.;Hitoshi Suzuki.;Vladimir Tesař.;Hernán Trimarchi.;Xuelian Wei.;Hong Zhang.;Jonathan Barratt.; .
来源: N Engl J Med. 2026年394卷7期647-657页
IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of patients, IgA nephropathy leads to kidney failure or death within 10 to 20 years after diagnosis. Atacicept is a native human transmembrane activator and calcium-modulator and cyclophilin-ligand interactor (TACI)-Fc fusion protein that inhibits two key immunoregulatory cytokines - B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) - that are thought to be central to the pathophysiology of IgA nephropathy.
|